期刊
ENDOCRINE-RELATED CANCER
卷 26, 期 4, 页码 R195-R209出版社
BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-19-0009
关键词
ErbB-2; castration-resistant prostate cancer; ErbB-2-targeting therapies; ErbB-2 regulation
资金
- National Institutes of Health [CA88184]
- US Department of Defense PCRP Grant [PC121645, PC141559]
- University of Nebraska Food for Health Grant
- University of Nebraska Medical Center Bridge Fund
- Buffet Cancer Center Pilot Project Grant
- University of Nebraska Medical Center Cancer Biology Training Grant [T32CA009476]
- University of Nebraska Medical Center Graduate Fellowship
- Purdue Pharma Scholars Award
Currently, prostate cancer (PCa) remains the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in US men. Most of these deaths are attributed to the development of castration-resistant (CR) PCa. ErbB-2 and ErbB family members have been demonstrated to contribute to the progression of this lethal disease. In this review, we focus on updating the role of ErbB-2 in advanced PCa progression and its regulation, including its regulation via ligand activation, miRNAs and protein phosphorylation. We also discuss its downstream signaling pathways, including AKT, ERK1/2 and STATs, involved in advanced PCa progression. Additionally, we evaluate the potential of ErbB-2, focusing on its protein hyper-phosphorylation status, as a biomarker for aggressive PCa as well as the effectiveness of ErbB-2 as a target for the treatment of CR PCa via a multitude of approaches, including orally available inhibitors, intratumoral expression of cPAcP, vaccination and immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据